ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Surgery was scheduled to occur within 6 weeks after the last neoadjuvant treatment; patients could then receive optional adjuvant therapy (up to four cycles of chemotherapy, radiotherapy, or both) per ...

The American University in Cairo's Research and Creativity Convention (RCC) brings together diverse research, design, entrepreneurship, innovation, and creativity projects to display their growth and ...

Robot-assisted partial cystectomy following neoadjuvant chemotherapy in selected patients may be a bladder-preserving option for patients with muscle-invasive bladder cancer. Robot-assisted ...

Potassium is a mineral needed for vital bodily functions. But people with kidney disease may need to know which high potassium foods to avoid. Here we discuss how to create such a diet. If you ...

Long-term follow-up showed that neoadjuvant pembrolizumab (Keytruda) and chemotherapy followed by surgery and adjuvant pembrolizumab continued to improve event-free (EFS) and overall survival (OS) ...

“Our findings suggest that durvalumab did not improve outcomes compared with cetuximab in patients with HNSCC with contraindications to cisplatin,” the authors concluded. “These findings are ...

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.

The approval was based on new research, which shows durvalumab (brand name Imfinzi) given with chemotherapy, followed by durvalumab given as a maintenance therapy, could significantly improve ...

In the phase 3 NIAGARA trial (NCT03732677), the combination of neoadjuvant durvalumab (Imfinzi) plus chemotherapy, followed by adjuvant durvalumab, led to significantly improved ... Belzutifan ...